Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial

Clinical Immunology

Volumn 169, Issue , 2016, Pages 16-27

  Leroux Roels, Geert ^a   Marchant, Arnaud ^b,c   Levy, Jack ^b,d   Van Damme, Pierre ^e   Schwarz, Tino F ^f   Horsmans, Yves ^g   Jilg, Wolfgang ^h   Kremsner, Peter G ⁱ   Haelterman, Edwige ^b   Clément, Frédéric ^a   Gabor, Julian J ⁱ   Esen, Meral ⁱ   Hens, Annick ^e   Carletti, Isabelle ^j   Fissette, Laurence ^j   Tavares Da Silva, Fernanda ^j   Burny, Wivine ^j   Janssens, Michel ^j   Moris, Philippe ^j   Didierlaurent, Arnaud M ^j   Van Der Most, Robbert ^j   Garçon, Nathalie ^j,k   Van Belle, Pascale ^j   Van Mechelen, Marcelle ^j   more..

^a GHENT UNIVERSITY   (Belgium)

^b ImmuneHealth   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^h UNIVERSITY OF REGENSBURG   (Germany)

ⁱ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^j GSK   (Belgium)

^k BIOASTER   (France)

more..

Author keywords

Adaptive immune response; Adjuvant system; CD4+ T cell; Hepatitis B virus surface antigen; Memory B cell; Polyfunctionality

Indexed keywords

ALUMINUM POTASSIUM SULFATE; AS 01B; AS 01E; AS 03A; AS 04; CD4 ANTIGEN; CD8 ANTIGEN; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; UNCLASSIFIED DRUG; HEPATITIS B ANTIBODY; VACCINE;

ADAPTIVE IMMUNITY; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; INJECTION SITE PAIN; MALE; MEMORY CELL; MULTICENTER STUDY; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; ANTIBODY PRODUCTION; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; IMMUNOASSAY; IMMUNOLOGY; LUMINESCENCE; PROCEDURES; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODY FORMATION; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOASSAY; LUMINESCENT MEASUREMENTS; MALE; VACCINATION; VACCINES;

EID: 84973522329     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.05.007     Document Type: Article

References (46)

1. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503. 10.1016/j.immuni.2010.10.002.
2. Glenny A., Pope C., Waddington H., Wallace U. The antigenic value of toxoid precipitated by potassium alum. J. Pathol. Bacteriol. 1926, 29:38-45.
3. Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 2007, 5:505-517. 10.1038/nrmicro1681.
4. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 2009, 9:287-293. 10.1038/nri2510.
5. Singh M., Ugozzoli M., Kazzaz J., Chesko J., Soenawan E., Mannucci D., et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 2006, 24:1680-1686. 10.1016/j.vaccine.2005.09.046.
6. Seder R.A., Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature 2000, 406:793-798. 10.1038/35021239.
7. Berzofsky J.A., Ahlers J.D., Janik J., Morris J., Oh S., Terabe M., Belyakov I.M. Progress on new vaccine strategies against chronic viral infections. J. Clin. Invest. 2004, 114:450-462. 10.1172/JCI22674.
8. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 2010, 28(Suppl. 3):C25-C36. 10.1016/j.vaccine.2010.07.021.
9. Pasquale A., Preiss S., Silva F., Garçon N. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines 2015, 3:320-343. 10.3390/vaccines3020320.
10. Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 2007, 6:723-739. 10.1586/14760584.6.5.723.
11. Garçon N., Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev. Vaccines 2011, 10:471-486. 10.1586/erv.11.29.
12. The RTS SCTP A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 2012, 367:2284-2295. 10.1056/NEJMoa1208394.
13. Bejon P., Cook J., Bergmann-Leitner E., Olotu A., Lusingu J., Mwacharo J., et al. Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J. Infect. Dis. 2011, 204:9-18. 10.1093/infdis/jir222.
14. Lal H., Cunningham A.L., Godeaux O., Chlibek R., Diez-Domingo J., Hwang S.J., et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N. Engl. J. Med. 2015, 372:2087-2096. 10.1056/NEJMoa1501184.
15. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589. 10.1016/S0140-6736(07)61297-5.
16. Leroux-Roels I., Bernhard R., Gerard P., Drame M., Hanon E., Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008, 3. 10.1371/journal.pone.0001665.
17. Nolan T., Roy-Ghanta S., Montellano M., Weckx L., Ulloa-Gutierrez R., Lazcano-Ponce E., et al. Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. J. Infect. Dis. 2014, 210:545-557. 10.1093/infdis/jiu173.
18. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24:5937-5949.
19. Szarewski A. Cervarix(R): a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types. Expert Rev. Vaccines 2012, 11:645-657. 10.1586/erv.12.42.
20. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev. Vaccines 2007, 6:133-140. 10.1586/14760584.6.2.133.
21. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S malaria vaccine evaluation group. N. Engl. J. Med. 1997, 336:86-91. 10.1056/NEJM199701093360202.
22. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 2009, 200:337-346. 10.1086/600120.
23. Chlibek R., Bayas J.M., Collins H., de la Pinta M.L., Ledent E., Mols J.F., et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age. J. Infect. Dis. 2013, 208:1953-1961. 10.1093/infdis/jit365.
24. Vandepapelière P., Horsmans Y., Moris P., Van Mechelen M., Janssens M., Koutsoukos M., et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008, 26:1375-1386. 10.1016/j.vaccine.2007.12.038.
25. Leroux-Roels G., Van B.P., Vandepapeliere P., Horsmans Y., Janssens M., Carletti I., et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination. Vaccine 2015, 33:1084-1091. 10.1016/j.vaccine.2014.10.078.
26. Diez-Domingo J., Garces-Sanchez M., Baldo J.M., Planelles M.V., Ubeda I., JuBert A., et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study. Pediatr. Infect. Dis. J. 2010, 29:e35-e46. 10.1097/INF.0b013e3181daf921.
27. Maecker H.T., Dunn H.S., Suni M.A., Khatamzas E., Pitcher C.J., Bunde T., et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods 2001, 255:27-40. 10.1016/S0022-1759(01)00416-1.
28. Crotty S., Aubert R.D., Glidewell J., Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J. Immunol. Methods 2004, 286:111-122. 10.1016/j.jim.2003.12.015.
29. Tavares Da Silva F., De Keyser F., Lambert P.H., Robinson W.H., Westhovens R., Sindic C. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine 2013, 31:1870-1876. 10.1016/j.vaccine.2013.01.042.
30. + T cells with diverse cytokine profiles. Nat. Med. 2005, 11:1113-1117. 10.1038/nm1293.
31. + T cells specific for defined antigens according to CD154 expression. Nat. Med. 2005, 11:1118-1124. 10.1038/nm1292.
32. + T lymphocytes produce multiple cytokines and proliferate in vivo in humans. J. Immunol. 2006, 177:8185-8190. 10.4049/jimmunol.177.11.8185.
33. Larsen M., Sauce D., Arnaud L., Fastenackels S., Appay V., Gorochov G. Evaluating cellular polyfunctionality with a novel polyfunctionality index. PLoS One 2012, 7. 10.1371/journal.pone.0042403.
34. Van Braeckel E., Bourguignon P., Koutsoukos M., Clement F., Janssens L., et al. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. Clin. Infect. Dis. 2011, 52(4):522-531. 10.1093/cid/ciq160.
35. Dendouga N., Fochesato M., Lockman L., Mossman S., Giannini S.L. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine 2012, 30:3126-3135. 10.1016/j.vaccine.2012.01.088.
36. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 2009, 183:6186-6197. 10.4049/jimmunol.0901474.
37. Morel S., Didierlaurent A., Bourguignon P., Delhaye S., Baras B., Jacob V., et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29:2461-2473. 10.1016/j.vaccine.2011.01.011.
38. Didierlaurent A.M., Collignon C., Bourguignon P., Wouters S., Fierens K., Fochesato M., et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J. Immunol. 2014, 193:1920-1930. 10.4049/jimmunol.1400948.
39. Flatz L., Roychoudhuri R., Honda M., Filali-Mouhim A., Goulet J.P., Kettaf N., et al. Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5724-5729. 10.1073/pnas.1013084108.
40. + cytotoxic T lymphocyte responses. J. Immunol. 1992, 148:2357-2362.
41. Mettens P., Dubois P.M., Demoitie M.A., Bayat B., Donner M.N., Bourguignon P., et al. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. Vaccine 2008, 26:1072-1082. 10.1016/j.vaccine.2007.12.018.
42. Pichyangkul S., Kum-Arb U., Yongvanitchit K., Limsalakpetch A., Gettayacamin M., Lanar D.E., et al. Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates. Infect. Immun. 2008, 76:229-238. 10.1128/IAI.00977-07.
43. Vandepapelière P., Rehermann B., Koutsoukos M., Moris P., Garçon N., Wettendorff M., et al. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine 2005, 23(20):2591-2601. 10.1016/j.vaccine.2004.11.034.
44. Thoelen S., Van Damme P., Mathei C., Leroux-Roels G., Desombere I., Safary A., et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998, 16:708-714.
45. Ambrosch F., Wiedermann G., Kundi M., Leroux-Roels G., Desombere I., Garcon N., et al. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 2000, 18:2095-2101.
46. Garçon N., Morel S., Didierlaurent A., Descamps D., Wettendorff M., Van Mechelen M. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs 2011, 25:217-226. 10.2165/11591760-000000000-00000.